Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma

Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.Materials and Methods We sequenced DNA from cell-free plasma that was s...

Full description

Saved in:
Bibliographic Details
Published inCancer research and treatment Vol. 56; no. 3; pp. 920 - 935
Main Authors Yoon, Sang Eun, Shin, Seung-Ho, Nam, Dae Keun, Cho, Junhun, Kim, Won Seog, Kim, Seok Jin
Format Journal Article
LanguageEnglish
Published Korea (South) Korean Cancer Association 01.07.2024
대한암학회
Subjects
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Circulating Tumor DNA - blood
Circulating Tumor DNA - genetics
Feasibility Studies
Female
Humans
Lymphoma, Follicular - blood
Lymphoma, Follicular - diagnosis
Lymphoma, Follicular - drug therapy
Lymphoma, Follicular - genetics
Lymphoma, Follicular - mortality
Male
Middle Aged
Mutation
Original
Prognosis
Rituximab - therapeutic use
Treatment Outcome
의학일반
Follicular lymphoma
Mutations
Prognosis
Circulating tumor DNA
Online AccessGet full text
ISSN1598-2998
2005-9256
2005-9256
DOI10.4143/crt.2023.869

Cover

Abstract Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.Results Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.Conclusion Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
AbstractList The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.PURPOSEThe feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.MATERIALS AND METHODSWe sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.RESULTSForty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.CONCLUSIONAnalysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear.Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes.Results Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression.Conclusion Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear. Materials and Methods We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes. Results Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression. Conclusion Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients. KCI Citation Count: 0
The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular lymphoma (FL) receiving systemic immunochemotherapy is not clear. We sequenced DNA from cell-free plasma that was serially obtained from newly diagnosed FL patients undergoing systemic immunochemotherapy. The mutation profiles of ctDNA at the time of diagnosis and at response evaluation and relapse and/or progression were compared with clinical course and treatment outcomes. Forty samples from patients receiving rituximab-containing immunochemotherapy were analyzed. Baseline sequencing detected mutations in all cases, with the major detected mutations being KMT2C (50%), CREBBP (45%), and KMT2D (45%). The concentration of ctDNA and tumor mutation burden showed a significant association with survival outcome. In particular, the presence of mutations in CREBBP and TP53 showed poor prognosis compared with patients without them. Longitudinal analysis of ctDNA using serially collected plasma samples showed an association between persistence or reappearance of ctDNA mutations and disease relapse or progression. Analysis of ctDNA mutations in plasma at diagnosis might help predict outcome of disease, while analysis during follow-up may help to monitor disease status of patients with advanced FL. However, the feasibility of ctDNA measurement must be improved in order for it to become an appropriate and clinically relevant test in FL patients.
Author Kim, Won Seog
Kim, Seok Jin
Shin, Seung-Ho
Nam, Dae Keun
Cho, Junhun
Yoon, Sang Eun
Author_xml – sequence: 1
  givenname: Sang Eun
  surname: Yoon
  fullname: Yoon, Sang Eun
– sequence: 2
  givenname: Seung-Ho
  surname: Shin
  fullname: Shin, Seung-Ho
– sequence: 3
  givenname: Dae Keun
  surname: Nam
  fullname: Nam, Dae Keun
– sequence: 4
  givenname: Junhun
  surname: Cho
  fullname: Cho, Junhun
– sequence: 5
  givenname: Won Seog
  surname: Kim
  fullname: Kim, Won Seog
– sequence: 6
  givenname: Seok Jin
  surname: Kim
  fullname: Kim, Seok Jin
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38228081$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003101109$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNqFkU1v1DAQhi1URLeFG2fkI0LNYjtObJ_QamGh0gpQtZwtx3G6po69tROq_Ps6bPkUEqfRaJ6Zd-adM3DigzcAPMdoSTEtX-s4LAki5ZLX4hFYEISqQpCqPgELXAleECH4KThL6StCNS0ZfgJOS04IRxwvwNXGqGQb6-wwwdDBtY16dGqw_hruxj5E-PbjCq68clOyCVoPP-ei8UOCd3bYw01wzs4dEW6n_rAPvXoKHnfKJfPsIZ6DL5t3u_WHYvvp_eV6tS00JWgoKqax4pwzwkwp2pLmrDUCV61ABDFct0p3uNOqaZVgBrOaNWWtO0SoUjVtynPw6jjXx07eaCuDst_jdZA3Ua6udpcSo6rClLIMF0d49Ac13Snn5CHaXsUpM3I2UmYj5WykzEZm_s2RP4xNb1qdL47qV88s9WfF230W_iYxJjXGgucJLx8mxHA7mjTI3iZtnFPehDFJkk8VAlNGM_rid7GfKj_elIGLI6BjSCma7n_Lk79wbYf8tjCvat2_m-4BE3W04Q
CitedBy_id crossref_primary_10_3390_ijms252011179
crossref_primary_10_1186_s13045_025_01673_7
crossref_primary_10_3343_alm_2024_0257
crossref_primary_10_1016_j_blre_2024_101237
Cites_doi 10.3324/haematol.2019.237719
10.1200/jco.19.01073
10.1200/jco.2013.54.8800
10.1182/blood-2017-08-737361
10.3324/haematol.2018.209015
10.1182/blood-2013-11-531327
10.1093/bioinformatics/btr509
10.1093/annonc/mdw400
10.1186/s13059-016-0974-4
10.1182/bloodadvances.2021006397
10.1200/jco.18.02365
10.1016/s1470-2045(15)00169-2
10.1182/blood-2005-01-0016
10.1182/bloodadvances.2021006415
10.1002/ajh.25696
10.1007/s00277-020-04008-3
10.1182/blood-2003-12-4434
10.1056/nejmoa1614598
10.1080/10428194.2019.1573998
10.1200/jco.2007.13.5376
10.3322/caac.21357
10.1093/jnci/djk152
10.1182/blood-2016-01-643569
10.1101/gr.107524.110
10.4143/crt.2022.017
10.3389/fonc.2023.1109715
10.1126/sciadv.abc4308
10.1186/s12885-021-08695-7
10.1200/jco.2014.59.7534
10.7150/jca.54434
10.4143/crt.2021.752
10.1038/s41572-019-0132-x
10.1182/blood-2015-01-621375
10.1016/s0140-6736(12)61763-2
10.1182/blood.2019000258
10.1038/nbt.3520
10.1200/jco.2012.45.2011
10.1182/blood-2008-05-154013
ContentType Journal Article
Copyright Copyright © 2024 by the Korean Cancer Association 2024
Copyright_xml – notice: Copyright © 2024 by the Korean Cancer Association 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
ACYCR
DOI 10.4143/crt.2023.869
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
Korean Citation Index
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
CrossRef

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2005-9256
EndPage 935
ExternalDocumentID oai_kci_go_kr_ARTI_10551447
10.4143/crt.2023.869
PMC11261198
38228081
10_4143_crt_2023_869
Genre Journal Article
GrantInformation_xml – fundername: National Research Foundation of Korea
  grantid: 2022R1F1A1064058
– fundername: National Research Foundation of Korea
  grantid: 2021R1A2C1007531
GroupedDBID ---
29B
5-W
53G
8JR
9ZL
AAYXX
ABDBF
ACUHS
ACYCR
ADBBV
AENEX
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
DIK
E3Z
EBD
EF.
F5P
HYE
OK1
RPM
TR2
C1A
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
M~E
ID FETCH-LOGICAL-c420t-57c1a888727e39d341a8de915d9020716dacf1fcabda97e1767b36cf024aa64b3
IEDL.DBID UNPAY
ISSN 1598-2998
2005-9256
IngestDate Sun Jul 14 10:40:56 EDT 2024
Wed Aug 20 00:03:51 EDT 2025
Thu Aug 21 18:32:53 EDT 2025
Thu Jul 10 23:37:52 EDT 2025
Thu Apr 03 07:04:49 EDT 2025
Tue Jul 01 03:18:52 EDT 2025
Thu Apr 24 23:04:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords Follicular lymphoma
Mutations
Prognosis
Circulating tumor DNA
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c420t-57c1a888727e39d341a8de915d9020716dacf1fcabda97e1767b36cf024aa64b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Sang Eun Yoon and Seung-Ho Shin contributed equally to this work.
ORCID 0000-0001-5624-1821
0000-0002-2776-4401
0000-0002-0379-5297
OpenAccessLink https://proxy.k.utb.cz/login?url=http://www.e-crt.org/upload/pdf/crt-2023-869.pdf
PMID 38228081
PQID 2915991474
PQPubID 23479
PageCount 16
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10551447
unpaywall_primary_10_4143_crt_2023_869
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11261198
proquest_miscellaneous_2915991474
pubmed_primary_38228081
crossref_primary_10_4143_crt_2023_869
crossref_citationtrail_10_4143_crt_2023_869
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-07-01
PublicationDateYYYYMMDD 2024-07-01
PublicationDate_xml – month: 07
  year: 2024
  text: 2024-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Korea (South)
PublicationPlace_xml – name: Korea (South)
PublicationTitle Cancer research and treatment
PublicationTitleAlternate Cancer Res Treat
PublicationYear 2024
Publisher Korean Cancer Association
대한암학회
Publisher_xml – name: Korean Cancer Association
– name: 대한암학회
References ref13
ref35
ref12
ref34
ref15
ref37
ref14
ref36
ref31
ref30
ref11
ref33
ref10
ref32
ref2
ref1
ref17
ref16
ref38
ref19
ref18
ref24
ref23
ref26
ref25
ref20
ref22
ref21
ref28
ref27
ref29
ref8
ref7
ref9
ref4
ref3
ref6
ref5
References_xml – ident: ref17
  doi: 10.3324/haematol.2019.237719
– ident: ref10
  doi: 10.1200/jco.19.01073
– ident: ref22
  doi: 10.1200/jco.2013.54.8800
– ident: ref26
  doi: 10.1182/blood-2017-08-737361
– ident: ref12
  doi: 10.3324/haematol.2018.209015
– ident: ref9
  doi: 10.1182/blood-2013-11-531327
– ident: ref29
  doi: 10.1093/bioinformatics/btr509
– ident: ref3
  doi: 10.1093/annonc/mdw400
– ident: ref31
  doi: 10.1186/s13059-016-0974-4
– ident: ref18
  doi: 10.1182/bloodadvances.2021006397
– ident: ref23
  doi: 10.1200/jco.18.02365
– ident: ref24
  doi: 10.1016/s1470-2045(15)00169-2
– ident: ref4
  doi: 10.1182/blood-2005-01-0016
– ident: ref19
  doi: 10.1182/bloodadvances.2021006415
– ident: ref20
  doi: 10.1002/ajh.25696
– ident: ref36
  doi: 10.1007/s00277-020-04008-3
– ident: ref21
  doi: 10.1182/blood-2003-12-4434
– ident: ref8
  doi: 10.1056/nejmoa1614598
– ident: ref34
  doi: 10.1080/10428194.2019.1573998
– ident: ref5
  doi: 10.1200/jco.2007.13.5376
– ident: ref2
  doi: 10.3322/caac.21357
– ident: ref7
  doi: 10.1093/jnci/djk152
– ident: ref1
  doi: 10.1182/blood-2016-01-643569
– ident: ref28
  doi: 10.1101/gr.107524.110
– ident: ref37
  doi: 10.4143/crt.2022.017
– ident: ref38
  doi: 10.3389/fonc.2023.1109715
– ident: ref32
  doi: 10.1126/sciadv.abc4308
– ident: ref33
  doi: 10.1186/s12885-021-08695-7
– ident: ref11
  doi: 10.1200/jco.2014.59.7534
– ident: ref15
  doi: 10.7150/jca.54434
– ident: ref35
  doi: 10.4143/crt.2021.752
– ident: ref25
  doi: 10.1038/s41572-019-0132-x
– ident: ref13
  doi: 10.1182/blood-2015-01-621375
– ident: ref6
  doi: 10.1016/s0140-6736(12)61763-2
– ident: ref14
  doi: 10.1182/blood.2019000258
– ident: ref30
  doi: 10.1038/nbt.3520
– ident: ref16
  doi: 10.1200/jco.2012.45.2011
– ident: ref27
  doi: 10.1182/blood-2008-05-154013
SSID ssj0064371
Score 2.3524992
Snippet Purpose The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with...
The feasibility of sequencing circulating tumor DNA (ctDNA) in plasma as a biomarker to predict early relapse or poor prognosis in patients with follicular...
SourceID nrf
unpaywall
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 920
SubjectTerms Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - blood
Biomarkers, Tumor - genetics
Circulating Tumor DNA - blood
Circulating Tumor DNA - genetics
Feasibility Studies
Female
Humans
Lymphoma, Follicular - blood
Lymphoma, Follicular - diagnosis
Lymphoma, Follicular - drug therapy
Lymphoma, Follicular - genetics
Lymphoma, Follicular - mortality
Male
Middle Aged
Mutation
Original
Prognosis
Rituximab - therapeutic use
Treatment Outcome
의학일반
Title Feasibility of Circulating Tumor DNA Analysis in Patients with Follicular Lymphoma
URI https://www.ncbi.nlm.nih.gov/pubmed/38228081
https://www.proquest.com/docview/2915991474
https://pubmed.ncbi.nlm.nih.gov/PMC11261198
http://www.e-crt.org/upload/pdf/crt-2023-869.pdf
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003101109
UnpaywallVersion publishedVersion
Volume 56
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Cancer Research and Treatment, 2024, 56(3), , pp.920-935
journalDatabaseRights – providerCode: PRVEBS
  databaseName: Academic Search Ultimate - eBooks
  customDbUrl: https://search.ebscohost.com/login.aspx?authtype=ip,shib&custid=s3936755&profile=ehost&defaultdb=asn
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: ABDBF
  dateStart: 20120301
  isFulltext: true
  titleUrlDefault: https://search.ebscohost.com/direct.asp?db=asn
  providerName: EBSCOhost
– providerCode: PRVBFR
  databaseName: Free Medical Journals - Free Access to All
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: DIK
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVERR
  databaseName: KoreaMed Open Access
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: 5-W
  dateStart: 20010101
  isFulltext: true
  titleUrlDefault: https://koreamed.org/journals
  providerName: Korean Association of Medical Journal Editors
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 2005-9256
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0064371
  issn: 1598-2998
  databaseCode: RPM
  dateStart: 20040101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Za9wwEB6SXWj70vtwj6DS46XIqW3Zlh43SZe0NEtaspA-CVmW0mU39uKsKdtf35GPJSFtyZONPUiWNGK-sWa-AXhrM8OFtbjTVMQoy0VOOQ8MtZzpOFGIoJVzFI8myeGUfTmNT7egL4LYRFVSXbXJBvVyUap8d5nbXXxEXaVvyhPh44NtGCbuSGkAw-nkePSjoUUVLqGgKX_bEGwKNOdtrDtDVOCa8F0TPnfRzZes0HZR2b8BzOtxkrfrYqnWv9RicckIje_Btz6Vp409mfv1KvP17-vMjjce33242yFSMmpV6AFsmeIh3DrqztwfwXdEiV0M7ZqUluzPKt3U_CrOyEl9XlbkYDIiPbkJmRXkuOVqvSDuJy8ZO9rvJtqVfF2j7pTn6jFMx59O9g9pV4mBahZ-XNE41YFCXxnBjolEjpZP8dyIIM4Fwk10uXKlbWC1ynIlUhOkSZpFibYIAJRKWBY9gUFRFuYZkCwO40hZdEtTxkJtlLU8VDqOwlRFWRR48KFfGak7mnJXLWMh0V1x6yhxqqSbKolT5cG7jfSypef4h9wbXGQ51zPp-LTd9ayU80qi1_BZuiKh6FimHrzulUDiLnNHJ6owZX0hQxwrImmWMg-etkqx6S_ijlKI45fzK-qyEXA9Xn1TzH42TN4ufysIBPfg_Uaz_juO5zcVfAF38Ja1gcUvYbCqavMK4dMq24HhaO9gb7zT7Zw_HzYaIg
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED9tnQR74RsWvmTExwtKRhInsR-rQTUQqwZapfFkXRx7VO2SKmuEyl_POUmrTQO0p0TJyY7ts-538d3vAN7Y3AhpLe00jLnPC1n4QoTGt4LrJEVC0OgcxaNxejjhX06T0y1YF0Fsoyp9XXfJBs1iXmGxvyjsPj3yXaVvX6QyoAfbsJO6I6UB7EzGx8MfLS2qdAkFbfnblmBTkjnvYt05oQLXROCaCISLbr5khbbL2v4NYF6Pk7zdlAtc_cL5_JIRGt2Fb-tUni72ZBY0yzzQv68zO954fPfgTo9I2bBTofuwZcoHcOuoP3N_CN8JJfYxtCtWWXYwrXVb86s8YyfNeVWzj-MhW5ObsGnJjjuu1gvmfvKykaP9bqNd2dcV6U51jo9gMvp0cnDo95UYfM2jD0s_yXSI5CsT2DGxLMjyoSiMDJNCEtwkl6tAbUOrMS9QZibM0iyPU20JACCmPI8fw6CsSrMHLE-iJEZLbmnGeaQNWisi1EkcZRjncejB-_XKKN3TlLtqGXNF7opbR0VTpdxUKZoqD95upBcdPcc_5F7TIquZnirHp-2uZ5Wa1Yq8hs_KFQklxzLz4NVaCRTtMnd0gqWpmgsV0VgJSfOMe_CkU4pNf7FwlEKCvlxcUZeNgOvx6pty-rNl8nb5W2EohQfvNpr133E8vangM9ilW94FFj-HwbJuzAuCT8v8Zb9j_gBWphiw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Feasibility+of+Circulating+Tumor+DNA+Analysis+in+Patients+with+Follicular+Lymphoma&rft.jtitle=Cancer+research+and+treatment&rft.au=%EC%9C%A4%EC%83%81%EC%9D%80&rft.au=%EC%8B%A0%EC%8A%B9%ED%98%B8&rft.au=%EB%82%A8%EB%8C%80%EA%B7%BC&rft.au=%EC%A1%B0%EC%A4%80%ED%9B%88&rft.date=2024-07-01&rft.pub=%EB%8C%80%ED%95%9C%EC%95%94%ED%95%99%ED%9A%8C&rft.issn=1598-2998&rft.eissn=2005-9256&rft.spage=920&rft.epage=935&rft_id=info:doi/10.4143%2Fcrt.2023.869&rft.externalDBID=n%2Fa&rft.externalDocID=oai_kci_go_kr_ARTI_10551447
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1598-2998&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1598-2998&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1598-2998&client=summon